Guidelines for Lidocaine 2 % Topical Gel Use in Pediatric Patients

Dosing and Maximum Exposure

For infants younger than 12 months or weighing less than 10 kg, the topical lidocaine dose should be reduced to minimize the risk of local anesthetic systemic toxicity (LAST). 1
When lidocaine is administered infiltratively without epinephrine, the maximum recommended dose is 1.5–2.0 mg kg⁻¹ per treatment. 2
When lidocaine is administered infiltratively with epinephrine, the maximum recommended dose is 3.0–4.5 mg kg⁻¹ per treatment. 2
The above limits apply to the total lidocaine exposure from all sources combined (topical, infiltrative, and intravenous) for a given procedure. 4

Topical lidocaine gel is indicated for procedures such as intravenous line placement/venipuncture, lumbar puncture, abscess drainage, and joint aspiration in pediatric patients. 1
Liposomal 4 % lidocaine cream (LMX4) achieves effective analgesia within ≈30 minutes of application. 1
EMLA® cream requires ≈60 minutes to reach full effectiveness. 1
Heat‑activated lidocaine systems may provide analgesia in 10–20 minutes. 1

Absolute contraindications for topical lidocaine in children include:
- Emergent need for IV access,
- Known allergy to amide‑type local anesthetics,
- Application to non‑intact skin,
- Recent sulfonamide antibiotic use (EMLA only), and
- Congenital or idiopathic methemoglobinemia (EMLA only). 1
Avoid contact with mucous membranes or ingestion of the gel to prevent systemic absorption. 1
Prior to any procedure, calculate the cumulative lidocaine dose from topical, infiltrative, and IV sources to ensure the total does not exceed the maximum safe limits. 4

For minimally invasive pediatric procedures, topical agents alone may be insufficient; consider adjunctive infiltrative anesthesia to achieve adequate analgesia. 2
Combining topical and infiltrative lidocaine can reduce the need for sedation or general anesthesia. 2
Perform incremental injections with aspiration before each dose to minimize the risk of inadvertent intravascular administration. 2

Current evidence does not support the use of topical lidocaine to lower peri‑operative respiratory adverse events in children who have an upper respiratory infection. 4
Some studies have reported an increased incidence of desaturation, laryngospasm, and bronchospasm when topical lidocaine is used in this population. 4

If signs of LAST occur, supportive airway management should be instituted promptly as part of the treatment protocol. 5